Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline...
November 06, 2025 07:00 ET | Source: Avenue Therapeutics

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
November 04, 2025 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback

Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy Designation Key aspects of a potential NDA application discussed and aligned with the Agency Praxis plans to...
November 03, 2025 11:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity

LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced a new publication in the journal Neuromodulation: Technology at the...
October 22, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
October 09, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and...
October 07, 2025 16:05 ET | Source: Neurona Therapeutics

Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)

Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)
October 03, 2025 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by...
September 29, 2025 08:00 ET | Source: Neura Health

Neura Health Secures $11.4 Million Series A to Fuel National Expansion of Comprehensive, Tech-Enabled Neurology Care Model

Neura Health Secures $11.4M Series A led by American Heart Association's Go Red for Women Venture Fund to expand tech-enabled neurology care model.
September 22, 2025 11:02 ET | Source: Angelini Pharma

Angelini Pharma sigla un accordo di opzione esclusiva con Sovargen per ottenere i diritti globali di sviluppo e commercializzazione di un asset innovativo nell'ambito della salute del cervello

Angelini Pharma ottiene un'opzione esclusiva per acquisire i diritti globali di sviluppo e commercializzazione al di fuori della Repubblica di Corea, della Cina, di Hong Kong, di Macao e Taiwan di...